Shkun Bhalla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shkun Bhalla has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
A. Brown
1 shared publicationA. Kielhorn
1 shared publication- Adrian Kielhorn
Eli Lilly Europe, Surrey, UK
1 shared publication - Alissa Brown
M-Tag Limited, Level 3, 109, Hammersmith Road, London, W14 OQH, UK
1 shared publication - Beenish Nafees
Icon PLC, Oxford, UK
1 shared publication - Dominic Tilden
M-TAG, London, UK
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 84
Health state utilities for non small cell lung cancer
Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.
- 1 January 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 84
Top Cited PapersOpen AccessHealth state utilities for non small cell lung cancer
Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.
- 14 April 2005
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 14 (2) , 141-142
Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer
Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity. The newer combination of gemcitabine plus cisplatin (GC) has demonstrated comparable survival and an improved toxicity profile (Von der Maase et al. 2000). At present, the importance to patients of the toxicity of chemotherapy has not been widely studied. An earlier study in bladder cancer indicated that toxicity was an important determinant of treatment preference (Davey et al. 2000). A study of preferences for advanced bladder cancer therapy in the UK was proposed.
- 14 April 2005
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 14 (2) , 141-142
Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer
Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity. The newer combination of gemcitabine plus cisplatin (GC) has demonstrated comparable survival and an improved toxicity profile (Von der Maase et al. 2000). At present, the importance to patients of the toxicity of chemotherapy has not been widely studied. An earlier study in bladder cancer indicated that toxicity was an important determinant of treatment preference (Davey et al. 2000). A study of preferences for advanced bladder cancer therapy in the UK was proposed.
- 1 February 2004
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 4 (1) , 27-38
Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer
A cost–utility analysis was conducted to compare the gemcitabine (Gemzar®)/cisplatin and methotrexate/vinblastine(Velban®)/doxorubicin (Doxil®)/cisplatin regimens in the treatment of locally advanced or metastatic bladder cancer. The analysis combined theresults of a cost analysis of a head-to-head Phase III clinical trial with those from a cross-sectional utility study. The analysis was performed from the perspective of the National Health Service in England and Wales. Medical resource use was obtained from the clinical trial database, from which patient-level cost streams were estimated for each treatment group. Unit costs for each resource utilization component were sought from the latest UK cost sources available at the time of analysis (2001). The distribution of the mean total and incremental costs for each group was simulated via bias-adjusted bootstrapping. Time trade-off utilities were derived from the utility study, which aimed to value the superior toxicity profile associated with gemcitabine/c...
- 1 February 2004
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 4 (1) , 27-38
Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer
A cost–utility analysis was conducted to compare the gemcitabine (Gemzar®)/cisplatin and methotrexate/vinblastine(Velban®)/doxorubicin (Doxil®)/cisplatin regimens in the treatment of locally advanced or metastatic bladder cancer. The analysis combined theresults of a cost analysis of a head-to-head Phase III clinical trial with those from a cross-sectional utility study. The analysis was performed from the perspective of the National Health Service in England and Wales. Medical resource use was obtained from the clinical trial database, from which patient-level cost streams were estimated for each treatment group. Unit costs for each resource utilization component were sought from the latest UK cost sources available at the time of analysis (2001). The distribution of the mean total and incremental costs for each group was simulated via bias-adjusted bootstrapping. Time trade-off utilities were derived from the utility study, which aimed to value the superior toxicity profile associated with gemcitabine/c...